

Drug resistance interpretation: PR

PI Major Mutations:

PI Accessory Mutations:

PR Other Mutations:

None

None

L10LV 1-10%, 0-40%
cons=0.387 • K20KR 4-50%, 0-30%
cons=0.235 • M36I 100%
cons=0.111 • R41K 90%
cons=0.141 • L63C 100%
cons=0.190 • I64V 90%
cons=0.190 • I72V 100%
cons=0.640

Protease Inhibitors

atazanavir/r (ATV/r)

Susceptible

darunavir/r (DRV/r)

Susceptible

fosamprenavir/r (FPV/r)

Susceptible

indinavir/r (IDV/r)

Susceptible

lopinavir/r (LPV/r)

Susceptible

nelfinavir (NFV)

Susceptible

saquinavir/r (SQV/r)

Susceptible

tipranavir/r (TPV/r)

Susceptible

PR comments

Other

- L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.
- K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

NRTI Mutations:	S68G <small>100% cons=0.840</small> • K70KT <small>0-10%, 0-20%</small> • T215F <small>90% cons=1.000</small>
NNRTI Mutations:	K103N <small>90% cons=0.300</small>
RT Other Mutations:	V35T <small>90% cons=0.100</small> • K49KR <small>0-40%, 0-10%</small> • V60I <small>100% cons=0.100</small> • A98S <small>90% cons=0.100</small> • K101R <small>90% cons=0.100</small> • K122E <small>90% cons=0.100</small> • I135IT <small>0-10%, 0-10%</small> • D177G <small>100% cons=0.100</small> • T200K <small>10% cons=0.100</small> • Q207E <small>90% cons=0.100</small> • R211K <small>100% cons=0.100</small> • P243PAS <small>0-10%, 0-10%, 0-10%</small> • V245K <small>100% cons=0.100</small> • E248ED <small>0-10%, 0-10%</small> • D250E <small>90% cons=0.100</small> • A554N <small>100% cons=0.100</small>

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Low-Level Resistance	doravirine (DOR)	Susceptible
zidovudine (AZT)	High-Level Resistance	efavirenz (EFV)	High-Level Resistance
stavudine (D4T)	Intermediate Resistance	etravirine (ETR)	Susceptible
didanosine (DDI)	Intermediate Resistance	nevirapine (NVP)	High-Level Resistance
emtricitabine (FTC)	Potential Low-Level Resistance	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Potential Low-Level Resistance		
tenofovir (TDF)	Low-Level Resistance		

RT comments	
NRTI	
<ul style="list-style-type: none">S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R.K70/E/Q/N/T/S/G cause low-level resistance to ABC and TDF.T215V/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF.	
NNRTI	
<ul style="list-style-type: none">K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.	

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

Drug resistance mutation scores of NRTI:								Download CSV	▼
Rule	ABC	AZT	D4T	DDI	FTC	3TC	TDF		
K70KT	15	0	15	15	10	10	15		
T215F	10	60	40	15	0	0	10		
Total	25	60	55	30	10	10	25		

Drug resistance mutation scores of NNRTI:						Download CSV	▼
Rule	DOR	EFV	ETR	NVP	RPV		
K103N	0	60	0	60	0		

INSTI Major Mutations:

None

INSTI Accessory Mutations:

None

IN Other Mutations:

K77Q A: 12%, Q: 38%,
cons:262 • S17N 100%,
cons:232 • M50L 100%,
cons:240 • L101I 100%,
cons:211 • T112M 17%,
cons:272 • T124A 100%,
cons:252 • T125A 94%,
cons:252 • D167DE D: 10%, E: 30%,
cons:262 • V201I 100%,
cons:212 • T206TS T: 67%, S: 33%,
cons:229 • T218I 100%,
cons:252 • K219Q 100%,
cons:252 • L234I 100%,
cons:252 • D256E 100%,
cons:242 • D286N 100%,
cons:252

Integrase Strand Transfer Inhibitors

bictegravir (BIC)

Susceptible

cabotegravir (CAB)

Susceptible

dolutegravir (DTG)

Susceptible

elvitegravir (EVG)

Susceptible

raltegravir (RAL)

Susceptible

No drug resistance mutations were found for INSTI.